Literature DB >> 15052512

Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study.

R Grohmann1, R R Engel, K H Geissler, E Rüther.   

Abstract

A considerable number of new drugs were introduced over the last few years. In this report we analyze to what extent they have come to be used in clinical practice and what changes in drug use have resulted from the availability of the new compounds. For this purpose, data on drug use in 1995 and 2001 assessed at two reference days per year and per hospital within the drug safety program AMSP were compared for 10 hospitals that had been participating in both years. Atypical neuroleptics (NL) were used in 59.9 % of patients on NLs in 2001 (16.7 % in 1995), most frequently olanzapine, risperidone, clozapine, and quetiapine, in this order. Thirty-nine percent of patients still received typical NLs in antipsychotic indication (77.1 % in 1995), and 30.8 % received typical hypnosedative NLs (38.1 % in 1995). SSRIs, other new ADs, and TCAs were used in similar rates in 2001, i. e., in 40.5 %, 37.9 %, and 34.8 % of AD patients, respectively (1995 : 24.2 %, 6.2 %, and 72.3 %, respectively). Mirtazapine was the most common AD in 2001, followed by citalopram, sertraline, and doxepin. Hypnotics were prescribed more frequently in 2001 (17.6 % vs. 11.7 %), mostly BZD agonists at that time, whereas overall anxiolytic use (in approximately 30 %) hardly changed over time. Mood stabilizers and anti-dementia drugs were given comparatively rarely, even in pertinent diagnoses. Polypharmacy was observed in about three-quarters of patients on psychotropic drugs, with a trend towards increasing use over time. Combinations of two NLs, of NL + AD, and of NLs + anxiolytic were most common in both years. Twenty percent of patients on atypical NLs received typical antipsychotic NLs additionally; typical hypnosedative NLs were used along with typical antipsychotics and atypical NLs in 20 % and 22 % of patients, respectively. TCAs and either SSRIs or other new ADs were still the most common AD combinations in 2001. Data were also analyzed according to the main diagnostic categories.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15052512     DOI: 10.1055/s-2004-815508

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  7 in total

Review 1.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

2.  Augmentation of olanzapine in treatment-resistant schizophrenia.

Authors:  Mathias Zink
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

3.  Principle standards and problems regarding proof of efficacy in clinical psychopharmacology.

Authors:  Hans-Jürgen Möller; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

4.  Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study.

Authors:  R Grohmann; R R Engel; H-J Möller; E Rüther; J W van der Velden; S Stübner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-07-09       Impact factor: 5.270

5.  Changes in the treatment of acute psychosis in a German public hospital from 1998 to 2004.

Authors:  Tiemo Wessels; Dandy Grünler; Christa Bunk; Michael Specka; Markus Gastpar; Norbert Scherbaum; Eugen Davids
Journal:  Psychiatr Q       Date:  2007-06

6.  Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study.

Authors:  W J Broekema; I W de Groot; P N van Harten
Journal:  Pharm World Sci       Date:  2007-02-27

7.  Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance Program.

Authors:  Michaela-Elena Friedrich; Elena Akimova; Wolfgang Huf; Anastasios Konstantinidis; Konstantinos Papageorgiou; Dietmar Winkler; Sermin Toto; Waldemar Greil; Renate Grohmann; Siegfried Kasper
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-20       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.